Status:

COMPLETED

Colon Staining Efficacy of Single Oral Doses of Methylene Blue MMX

Lead Sponsor:

Cosmo Technologies Ltd

Collaborating Sponsors:

Cross S.A.

Conditions:

Colon Staining in Preparation for Colonoscopy

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

To describe and evaluate the mucosal staining efficacy of Methylene Blue MMX® tablets after total oral doses of 150 or 200 mg in patients undergoing a full colonoscopy for various reasons.

Detailed Description

Objectives: To describe and evaluate the mucosal staining efficacy of Methylene Blue MMX® tablets after total oral doses of 150 or 200 mg in patients undergoing a full colonoscopy for various reasons...

Eligibility Criteria

Inclusion

  • Sex: males and females;
  • Age:18 to 70 years;
  • Colonoscopy: out-patients with indication for colonoscopy including faecal occult blood test positive colorectal cancer screening, polypectomy follow-up and inflammatory bowel disease check;
  • Contraception: either sterile subjects or subjects practising at least one reliable methods of contraception or in post-menopausal status for at least 1 year;
  • Informed Consent: signed written informed consent prior to inclusion in the study.

Exclusion

  • Pregnancy: pregnant or lactating women or at a risk of becoming pregnant;
  • Allergy: known or suspected hypersensitivity to the active principle and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general;
  • Diseases: known or suspected gastrointestinal obstruction or perforation, toxic megacolon, major colonic resection, inflammatory bowel diseases in active phase, severe diverticulosis with diverticulitis, heart failure (Class III or IV), serious cardiovascular disease, severe liver failure, end-stage renal insufficiency, any other relevant disease that might interfere with the aim of the study.
  • Comprehension: inability to comprehend the full nature and purpose of the study and unwillingness to co-operate with the Investigator and to comply with the requirements of the entire study.

Key Trial Info

Start Date :

May 2 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 16 2012

Estimated Enrollment :

114 Patients enrolled

Trial Details

Trial ID

NCT03287219

Start Date

May 2 2011

End Date

January 16 2012

Last Update

January 28 2021

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.